Kirilys Therapeutics Announces FDA Clearance of IND Application for KRLS-017, a reversible inhibitor of CDK7 for Oncology
Phase 1 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KRLS-017 in treatment refractory solid tumors San Francisco, CA, April 28, 2023 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, today announced the Food and Drug Administration (FDA) has cleared the Investigational […]